Plain-English translation of NCT03003533 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial tested SPK-8011, a new gene therapy designed to help people with hemophilia A produce their own blood-clotting protein. Researchers studied whether a single intravenous infusion of this treatment could help participants' bodies make enough clotting factor on their own, potentially reducing or eliminating the need for regular clotting factor injections.
Hemophilia A causes severe and repeated bleeding episodes that can damage joints and significantly impact quality of life. While current treatments work, they require frequent injections or infusions. This medication was developed as a potential one-time treatment that could give patients' bodies the ability to produce their own clotting factor naturally.
Participants received a single intravenous infusion of the treatment at different dose levels as part of a dose-escalation study. The trial investigated whether the medication was safe and whether it could help participants' bodies produce clotting factor naturally. Participants were monitored for safety and effectiveness throughout the study period.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States